Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals has demonstrated a positive outlook primarily through the successful expansion of its Cortrophin sales force in early 2025, which has significantly contributed to the product's success. The company’s data-driven approach, supported by its weekly TRx tracker, indicates that Cortrophin is poised to outperform previous revenue expectations, consequently leading to potential revenue estimate increases and multiple expansions. Furthermore, ANI's enhanced capability to address payer-related inquiries and secure script approvals positions the company favorably for ongoing financial growth.

Bears say

ANI Pharmaceuticals Inc. faces multiple significant risks that contribute to a negative outlook on its stock, including a considerable debt load exceeding $600 million, which may limit financial flexibility and operational investments. Additionally, the company is subject to pricing pressures across its portfolio of branded and generic drugs, as well as reimbursement uncertainties that may impact revenue stability. Other risks include challenges related to commercial execution, manufacturing vulnerabilities, and competitive threats, exacerbated by a history of reputational concerns in the ACTH category that could affect market perception.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.